Brinton Seashore-Ludlow 1 , Matthew G Rees 1 , Jaime H Cheah 1 , Murat Cokol 2 , Edmund V Price 1 , Matthew E Coletti 1 , Victor Jones 1 , Nicole E Bodycombe 1 , Christian K Soule 1 , Joshua Gould 1 , Benjamin Alexander 1 , Ava Li 1 , Philip Montgomery 1 , Mathias J Wawer 1 , Nurdan Kuru 2 , Joanne D Kotz 1 , C Suk-Yee Hon 1 , Benito Munoz 1 , Ted Liefeld 1 , Vlado Dančík 1 , Joshua A Bittker 1 , Michelle Palmer 1 , James E Bradner 3 , Alykhan F Shamji 4 , Paul A Clemons 4 , Stuart L Schreiber 1
Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) profiling of small-molecule sensitivity has emerged as an unbiased method to assess the relationships between genetic or cellular features of CCLs and small-molecule response. Here, we developed annotated cluster multidimensional enrichment analysis to explore the associations between groups of small molecules and groups of CCLs in a new, quantitative sensitivity dataset. This analysis reveals insights into small-molecule mechanisms of action, and genomic features that associate with CCL response to small-molecule treatment. We are able to recapitulate known relationships between FDA-approved therapies and cancer dependencies and to uncover new relationships, including for KRAS-mutant cancers and neuroblastoma. To enable the cancer community to explore these data, and to generate novel hypotheses, we created an updated version of the Cancer Therapeutic Response Portal (CTRP v2).